Andrew J. Pierce

High Impact

Senior Vice President

Ouachita Baptist University

Also affiliated: AstraZeneca (United Kingdom) (2015–2024); University of North Carolina at Chapel Hill (1992–2020); The Graduate Center, CUNY (2010); Babraham Institute (2024); Memorial Sloan Kettering Cancer Center (1999–2005); University of Kentucky (2004–2014); University of South Carolina (2010); Cornell University (1999–2002); Durham Technical Community College (1997); Markey Cancer Center (2004–2020); University of Florida (2016); Humboldt-Universität zu Berlin (2005); Syngenta (United Kingdom) (2025); AstraZeneca (France) (2018–2020); AstraZeneca (Singapore) (2020–2021); AstraZeneca (Brazil) (2021); Dana-Farber Cancer Institute (2005); AstraZeneca (Japan) (2018); Altimmune (United States) (2015); AstraZeneca (United States) (2018); Napp Pharmaceuticals (United Kingdom) (2018); US Biologic (United States) (2021); UNC Lineberger Comprehensive Cancer Center (1992); Crescendo Biologics Ltd. (United Kingdom) (2021–2024); King Mongkut's University of Technology Thonburi (2011–2025); Charité - Universitätsmedizin Berlin (2005); Syngenta (Switzerland) (2025)

34 h-index 170 pubs 7,743 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Andrew J. Pierce's research focuses on DNA repair mechanisms in mammalian cells, particularly homology-directed repair (HDR). His work has investigated the roles of specific proteins, such as XRCC3 and BRCA2, in promoting the accurate repair of DNA double-strand breaks. Pierce has also explored how factors like the Ku DNA end-binding protein and the Fanconi anemia pathway influence these repair processes and their potential mutagenic consequences.

His research extends to understanding how cellular processes, including transcription and the regulation of RecA homologs, can lead to drug resistance in cancer cells, as exemplified by studies involving BCR/ABL. Pierce's publications span several decades, with significant contributions to the understanding of fundamental molecular biology relevant to genetics and neoplasm development. His scholarly output is marked by a high citation count and an h-index of 34, indicating a substantial impact in his field. Pierce is recognized as a highly cited researcher, and his work remains recently active.

Metrics

h-index: 34
Publications: 170
Citations: 7,743

Positions

Senior Vice President 2024–present

Owkin, Inc. Discovery and Development ORCID
Senior Vice President publications 2025

Ouachita Baptist University ORCID
Vice President 2020–2024

Crescendo Biologics Ltd Translational Biology ORCID
Associate Director 2014–2020

AstraZeneca R&D Cambridge Translational Medicine ORCID
Senior Scientist 2011–2014

AstraZeneca Medimmune Translational Medicine ORCID
Oncology Biomarker Analyst 2010–2011

N-of-One Therapeutics ORCID
Assistant Professor 2003–2011

University of Kentucky Microbiology, Immunology and Molecular and Cellular Biology ORCID

Selected Publications

Quantifying Resilience in Single-Host/Single-Virus Infections (2025)

Applied Microbiology DOI OpenAlex
Quantifying Resilience in Single-Host/Single-Virus Infections (2025)

Preprints.org DOI OpenAlex